- In November 2024, Shuttle Pharma has expanded its Phase II trial of ropidoxuridine for glioblastoma patients, with the first cohort dosed at cancer centers across the US. The treatment, which combines with radiation therapy, is being tested for its potential in combating glioblastoma. This expansion will enhance the company's position in the glioblastoma treatment market, demonstrating its commitment to advancing innovative cancer therapies
- In July 2024, aTyr Pharma, Inc. has signed a research agreement with Stanford Medicine, with Dr. Michael Lim, Chair of Neurosurgery, serving as the principal investigator. Dr. Lim’s research will focus on the mechanisms of immunosuppression in glioblastoma multiforme (GBM). This collaboration will enhance aTyr Pharma's expertise and research capabilities, advancing its efforts to develop novel immunotherapies for GBM
